Technical Analysis for XBIO - Xenetic Biosciences, Inc.

Grade Last Price % Change Price Change
B 4.10 0.37% 0.02
XBIO closed up 0.37 percent on Friday, November 1, 2024, on 2.65 times normal volume. It was able to find support at its 50 day moving average. It was able to bounce off of its 200 day moving average, an important long-term support line.
Earnings due: Nov 7
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
200 DMA Support Bullish 0.00%
50 DMA Support Bullish 0.00%
MACD Bullish Centerline Cross Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Upper Bollinger Band Touch Strength 0.00%
Gapped Down Weakness 0.00%
Inside Day Range Contraction 0.37%
Gapped Down Weakness 0.37%

   Recent Intraday Alerts

Alert Time
Up 3% about 19 hours ago
Up 2% about 19 hours ago
Up 1% about 19 hours ago
20 DMA Support about 21 hours ago
10 DMA Support about 21 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Xenetic Biosciences, Inc. Description

Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company's platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company's technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company's lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Pharmaceutical Products FDA Acute Myeloid Leukemia Kidney Disease Dialysis Anemia Chronic Kidney Disease Drug Therapies Platform Technologies Endometrial Cancer Refractory Acute Myeloid Leukemia Erythropoietin Growth Factors

Is XBIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.175
52 Week Low 2.78
Average Volume 13,784
200-Day Moving Average 3.95
50-Day Moving Average 3.94
20-Day Moving Average 3.86
10-Day Moving Average 3.86
Average True Range 0.32
RSI (14) 54.95
ADX 23.17
+DI 22.10
-DI 15.83
Chandelier Exit (Long, 3 ATRs) 3.78
Chandelier Exit (Short, 3 ATRs) 4.51
Upper Bollinger Bands 4.27
Lower Bollinger Band 3.46
Percent B (%b) 0.79
BandWidth 20.85
MACD Line 0.02
MACD Signal Line -0.03
MACD Histogram 0.0435
Fundamentals Value
Market Cap 6.32 Million
Num Shares 1.54 Million
EPS -2.90
Price-to-Earnings (P/E) Ratio -1.41
Price-to-Sales 2.53
Price-to-Book 0.55
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.91
Resistance 3 (R3) 4.90 4.63 4.78
Resistance 2 (R2) 4.63 4.42 4.63 4.73
Resistance 1 (R1) 4.36 4.29 4.50 4.37 4.68
Pivot Point 4.09 4.09 4.15 4.09 4.09
Support 1 (S1) 3.82 3.88 3.96 3.83 3.52
Support 2 (S2) 3.55 3.75 3.55 3.47
Support 3 (S3) 3.28 3.55 3.43
Support 4 (S4) 3.29